Latest News on ROIV

Financial News Based On Company


Advertisement
Advertisement

In his first ownership report, Roivant Sciences (ROIV) director Jeffrey Evan Hammerbacher lists no holdings.

https://www.stocktitan.net/sec-filings/ROIV/form-3-roivant-sciences-ltd-initial-statement-of-beneficial-ownership-9d7ca3582c7d.html
Jeffrey Evan Hammerbacher, a director at Roivant Sciences Ltd. (ROIV), filed an initial ownership report (Form 3) stating he beneficially owns no securities of the company. This report, accepted by the SEC on November 19, 2026, indicates his status as a director without any direct or indirect holdings in the company's stock.

Form 4 Roivant Sciences Ltd.: Daniel Allen Gold (Director) For: 16 November

https://uk.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-daniel-allen-gold-director-for-16-november-93CH-4991888
This article reports on a Form 4 filing for Roivant Sciences Ltd., indicating an insider transaction by Daniel Allen Gold, a director, on November 16. The specific details of the transaction are not provided within the text, but the filing itself signals a change in beneficial ownership that is reported to the SEC.

Keith Manchester Sells $54M Of Roivant Sciences Stock After Sharp Run-Up

https://www.benzinga.com/trading-ideas/insider-trades/26/11/63426082/keith-manchester-sells-54m-of-roivant-sciences-stock-after-sharp-run-up
Keith Manchester sold 1,381,762 shares of Roivant Sciences Ltd. (NASDAQ:ROIV) for $53.5 million on November 16, 2026, reducing his holdings by 6.68%. This sale followed a significant run-up in Roivant shares, which had climbed over 15% in the month prior to the transaction. Despite a slight dip since the sale, the stock has shown strong performance over the past year, gaining 87.29%.

Form 4 Roivant Sciences Ltd.: QVT Financial LP (Director by Deputization) For: 16 November

https://uk.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-qvt-financial-lp-director-by-deputization-for-16-november-93CH-4991839
This article reports on a Form 4 filing for Roivant Sciences Ltd., specifically detailing a transaction related to QVT Financial LP, which holds a Director by Deputization role. The filing pertains to activity on November 16. The content provides the title and a reconfirmation of the Form 4 details.

Alongside two days of Roivant Sciences (ROIV) stock sales, QVT entities distributed shares without payment.

https://www.stocktitan.net/sec-filings/ROIV/form-4-roivant-sciences-ltd-insider-trading-activity-7fda5ccd6f45.html
QVT entities, associated with Roivant Sciences director Daniel Allen Gold, reported significant sales of ROIV common shares on November 16 and 17, 2026, across several of its investment vehicles. Additionally, on November 17, three QVT entities conducted pro rata in-kind distributions of over 3 million shares for no consideration. These transactions highlight substantial insider activity involving Roivant Sciences stock.
Advertisement

Form 4 Roivant Sciences Ltd.: Keith S. Manchester (Director) For: 16 November

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-keith-s-manchester-director-for-16-november-93CH-4968202
This article reports on a Form 4 filing for Roivant Sciences Ltd., indicating that Director Keith S. Manchester made a transaction on November 16. The brief news item was published on Investing.com, a financial markets news platform.

Roivant CEO Matt Gline: AI Won't Cure All Disease, and Biotech Is a "Wood Chipper for Souls"

https://finance.biggo.com/news/3d1a4cdf67780de5
Roivant CEO Matt Gline and Affinity Asset Advisors' Patrick Nosker shared their candid views on biotech at the Jefferies Healthcare Conference, asserting that biotech is an arduous industry and AI's initial impact will be limited to "me-too" drugs due to shared training data. They also discussed how markets often misinterpret early drug launch data, emphasizing that the peak revenue, not the initial trajectory, is what truly matters for valuations. The real test for Roivant's Immunovant comes in 2027 with Phase 3 data for Graves disease, an indication with no prior clinical trials to model against.

Form 144 ROIVANT SCIENCES LTD For: 15 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-roivant-sciences-ltd-for-15-november-93CH-2808675
This article from Investing.com announces the filing of Form 144 for Roivant Sciences Ltd. on November 15, 2026. Form 144 relates to the proposed sale of restricted securities. The brief notice provides a direct link to the filing information.

Form 144 ROIVANT SCIENCES LTD. For: 14 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-roivant-sciences-ltd-for-14-november-93CH-2808137
This article reports on a Form 144 filing by ROIVANT SCIENCES LTD. for November 14th, indicating an intent to sell restricted securities. The filing is a standard regulatory disclosure and provides minimal detail beyond the company name and date. ROIVANT SCIENCES LTD. (ROIV) is noted with a -1.15% change in this context.

Form 144/A Roivant Sciences Ltd. Filed by: Pulik Richard

https://www.streetinsider.com/SEC+Filings/Form+144A+Roivant+Sciences+Ltd.+Filed+by%3A+Pulik+Richard/27345685.html
Roivant Sciences Ltd. (ROIV) had a Form 144/A filed by Pulik Richard, as reported by StreetInsider.com. The article also mentions that Bernstein SocGen Group raised their price target for Roivant Sciences to $44.
Advertisement

Form 144/A Roivant Sciences Ltd. Filed by: Pulik Richard

https://www.streetinsider.com/SEC+Filings/Form+144A+Roivant+Sciences+Ltd.+Filed+by%3A+Pulik+Richard/27345687.html
Pulik Richard has filed a Form 144/A with the SEC concerning Roivant Sciences Ltd. This filing indicates an intent to sell restricted securities. The article also includes general market news and analyst ratings on other companies.

Form 4 Roivant Sciences Ltd.: Matthew Gline (Director, CEO) For: 10 November

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-matthew-gline-director-ceo-for-10-november-93CH-4955246
This article reports on a Form 4 filing for Roivant Sciences Ltd., detailing a transaction involving Matthew Gline, who serves as a Director and CEO of the company. The filing is related to activity on November 10th. The brief announcement provides no further details on the nature of the transaction.

Tax-cover sales by Roivant Sciences (ROIV) president accompany a two-year hold on remaining settlement shares.

https://www.stocktitan.net/sec-filings/ROIV/form-4-roivant-sciences-ltd-insider-trading-activity-3221a0394c37.html
Roivant Sciences' President and Vant Chair, Frank Torti, reported direct sales of common shares between November 10-12, 2026. These "sell-to-cover" transactions were executed to satisfy tax withholding obligations following the vesting of performance restricted stock units (PSUs). The remaining common shares issued from the settlement are subject to a two-year post-vesting holding period.

Form 4 Roivant Sciences Ltd.: Frank Torti (President and Vant Chair) For: 10 November

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-frank-torti-president-and-vant-chair-for-10-november-93CH-4955250
This article reports on a Form 4 filing for Roivant Sciences Ltd. concerning Frank Torti, who serves as President and Vant Chair. The filing pertains to activity on November 10. The article is a brief news update from Investing.com, noting the company's stock symbol ROIV.

Form 4 Roivant Sciences Ltd.: Richard Pulik (CFO) For: 10 November

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-richard-pulik-cfo-for-10-november-93CH-4954952
This article reports on a Form 4 filing for Roivant Sciences Ltd., specifically noting a transaction involving Richard Pulik, the CFO, on November 10th. The filing indicates insider trading activity for the company, which is identified by the stock symbol ROIV.
Advertisement

$3.85 options exercised as Roivant Sciences (ROIV) CFO sells shares above $41.

https://www.stocktitan.net/sec-filings/ROIV/form-4-roivant-sciences-ltd-insider-trading-activity-a74f2e822204.html
Roivant Sciences Ltd.'s CFO, Richard Pulik, exercised options for 125,000 common shares on November 10, 2026, and 127,365 shares on November 11, 2026, both at an exercise price of $3.85 per share. Concurrently, he sold 125,000 shares on November 10 at $41.20 per share, and on November 11, he sold additional blocks of shares at weighted average prices between $41.47 and $42.03. These transactions involved a total approximate gross sale proceeds of $12.47 million against an approximate exercise cost of $972,000, with all options being fully vested.

Roivant Sciences CFO Sold Shares Worth Over $12M

https://www.tradingview.com/news/tradingview:afdc89df0e1a7:0-roivant-sciences-cfo-sold-shares-worth-over-12m/
Roivant Sciences CFO Pulik Richard sold 300,000 Common Shares in multiple transactions on November 10 and 11, 2026, totaling over $12.4 million. The sales were executed at weighted average prices ranging from $41.20 to $41.89 per share. Following these transactions, Richard's direct ownership in Roivant Sciences decreased to 222,046 Common Shares.

How Trial Wins And Drug Launch Revenue Will Impact Roivant Sciences Stock (ROIV)

https://sg.finance.yahoo.com/news/trial-wins-drug-launch-revenue-071436471.html
Roivant Sciences reported Q2 2026 revenue of US$35.12 million and a net loss of US$191.62 million, alongside the completion of a US$393.94 million share repurchase. The company's new drug, LISRIA, generated US$31 million in net revenue during its initial commercial weeks, supported by positive data from other clinical programs. The article examines how these developments, including early product uptake and clinical progress, are reshaping Roivant's investment narrative.

Form 144 Roivant Sciences Ltd. For: 11 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-roivant-sciences-ltd-for-11-november-93CH-4973818
This article announces the filing of Form 144 by Roivant Sciences Ltd. on November 11. Form 144 is a notice of the intent to sell restricted securities. The article provides this key information without further details or analysis.

Form 144/A Roivant Sciences Ltd. Filed by: Torti Frank

https://www.streetinsider.com/SEC+Filings/Form+144A+Roivant+Sciences+Ltd.+Filed+by%3A+Torti+Frank/27324753.html
This article reports on a Form 144/A filing by Torti Frank regarding Roivant Sciences Ltd. (ROIV). The filing is a public disclosure related to the proposed sale of restricted securities by an affiliate of the issuer. The main content of the article consists of the filing details and navigation links to financial news and tools.
Advertisement

Roivant Sciences Q2 2027 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63032052/roivant-sciences-q2-2027-earnings-call-transcript
Roivant Sciences reported strong Q2 2027 financial results, including $31 million in net revenue from the initial commercial launch of Lysraya, indicating high demand. The company also announced significant clinical advancements, with positive data in rheumatoid arthritis, cutaneous sarcoidosis, and PH-ILD, and plans for new indications and an Investor Day in December. Management expressed optimism about the company's trajectory, driven by robust clinical data and recent developments.

Earnings call transcript: Roivant Sciences tops Q2 2026 estimates on LISRAYA launch

https://www.investing.com/news/transcripts/earnings-call-transcript-roivant-sciences-tops-q2-2026-estimates-on-lisraya-launch-93CH-5012325
Roivant Sciences reported stronger-than-expected Q2 2026 results, driven by the initial commercial sales of LISRAYA, its newly approved dermatomyositis treatment, which generated $31 million in net revenue. The company also announced positive data from its IMVT-1402 rheumatoid arthritis study and highlighted progress in its non-infectious uveitis and pulmonary hypertension programs. Despite ongoing losses, Roivant maintains a strong liquidity position and is focused on expanding its commercial footprint and advancing its pipeline.

Roivant Sciences Ltd. (ROIV) Tops Q2 EPS by 10c

https://www.streetinsider.com/Earnings/Roivant+Sciences+Ltd.+%28ROIV%29+Tops+Q2+EPS+by+10c/27311148.html
Roivant Sciences Ltd. (ROIV) announced its Q2 earnings, reporting an EPS of ($0.27), which was $0.10 better than the analyst estimate of ($0.37). The company's revenue for the quarter was $35.12 million, significantly exceeding the consensus estimate of $3.74 million. This positive earnings surprise led to a 4.55% increase in the stock price on the day.

ROIV: Roivant Sciences Ltd. filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/roivant-sciences-ltd-filed-sec-form-8-k-results-of-operations-6780177
Roivant Sciences Ltd. (ROIV) filed an SEC Form 8-K reporting results for the quarter ended September 30, 2026, with a net loss of $191.6 million, an increase from $113.5 million a year prior, primarily due to a non-cash distribution. Despite the loss, the company's new drug, LISRAYA, generated $31.0 million in net product revenue in its first five weeks, and Roivant maintains a strong cash position of $4.2 billion. Additionally, brepocitinib met its primary and key secondary endpoints in Phase 3 trials, with an sNDA expected in H1 2027.

Revenue reaches $35.1M at Roivant Sciences (ROIV), but the quarterly loss widens.

https://www.stocktitan.net/sec-filings/ROIV/10-q-roivant-sciences-ltd-quarterly-earnings-report-ad57de423697.html
Roivant Sciences Ltd. (ROIV) reported $35.1 million in revenue for the three months ended September 30, 2026, a significant increase from $1.6 million in the year-ago quarter, driven by $31.0 million in product revenue from LISRAYA after its August 2026 FDA approval. Despite the revenue growth, the company's net loss attributable to Roivant widened to $191.6 million, compared to $113.5 million in the prior year, primarily due to increased operating expenses and a lower change in fair value of investments. The company maintains a strong liquidity position with approximately $4.2 billion in cash, cash equivalents, and marketable securities as of September 30, 2026, providing a runway into profitability.
Advertisement

Roivant Sciences Ltd. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ROIV) 2026-11-09

https://seekingalpha.com/article/4965133-roivant-sciences-ltd-2026-q2-results-earnings-call-presentation
Roivant Sciences Ltd. published its 2026 Q2 earnings call presentation. The company reported an EPS of -$0.18, beating estimates by $0.26, and revenue of $35.12M, significantly surpassing expectations by $30.82M with a 2,135.58% year-over-year increase. This article provides the slide deck in conjunction with their earnings call.

Roivant Sciences Ltd. (ROIV) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ROIV/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for Roivant Sciences Ltd. (ROIV), showing the average monthly price return from 2020 to 2026. It also includes current stock information, recent price changes, and details about an upcoming earnings call. The page seems to have experienced a display error ("Oops, something went wrong") but still presents key financial data.

Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years

https://www.benzinga.com/news/26/11/63016068/here-s-how-much-you-would-have-made-owning-roivant-sciences-stock-last-5-years
Roivant Sciences (NASDAQ: ROIV) has significantly outperformed the market over the last five years, with an annualized return of 35.57%. An investment of $100 in ROIV five years ago would now be worth $511.58. The article highlights the power of compounded returns over time.

Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 3 November

https://uk.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-eric-venker-president--immunovant-ceo-for-3-november-93CH-4962951
This article reports on a Form 4 filing for Roivant Sciences Ltd., specifically noting a transaction by Eric Venker, who holds the titles of President and Immunovant CEO, relating to November 3. The filing is an important disclosure for investors, offering transparency into executive holdings and transactions within the company. The article also mentions the stock symbols IMVT and ROIV, which were down 5.05% and 4.21% respectively, at the time of publication.

Under a trading plan, Eric Venker sold 200,000 Roivant Sciences (ROIV) shares.

https://www.stocktitan.net/sec-filings/ROIV/form-4-roivant-sciences-ltd-insider-trading-activity-d7aed255f3a0.html
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), sold 200,000 common shares on November 3, 2026, at a weighted-average price of $36.31 per share. The transactions, ranging from $35.75 to $36.70 per share, were conducted under a Rule 10b5-1 trading plan adopted on June 30, 2026. Following the sale, Venker directly holds 999,154 common shares.
Advertisement

Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value

https://sg.finance.yahoo.com/news/roivant-sciences-roiv-stock-looks-061348850.html
Roivant Sciences (ROIV) stock has seen significant gains, leading to questions about whether its current share price aligns with its book value. The company's P/B ratio of 6.5x is higher than the biotech sector average, indicating investors are paying a premium for its assets. While some narratives suggest the company is undervalued due to its pipeline, others argue it's overvalued given its high market capitalization.

Roivant Sciences Ltd (87S.MU) Seasonal returns chart

https://sg.finance.yahoo.com/quote/87S.MU/seasonality/
This article from Yahoo Finance presents the seasonal returns chart for Roivant Sciences Ltd (87S.MU). It displays the average monthly price return for the company between 2022 and 2026. The page also includes current stock information, showing the stock trading at 33.68 EUR, up 4.26%.

Roivant Sciences Officer Eric Venker to Sell 200,000 Shares Valued at $7.26 Million

https://kalkinemedia.com/us/news/announcements/roivant-sciences-officer-eric-venker-to-sell-200000-shares-valued-at-726-million
Roivant Sciences Ltd. officer Eric Venker plans to sell 200,000 common shares worth $7.26 million through Rockefeller Financial LLC on the NASDAQ exchange, as revealed in a Form 144 notice filed on November 3, 2026. This sale will be conducted under a Rule 10b5-1 trading plan adopted on June 30, 2026, and follows previous sales totaling over $29 million in the preceding three months. The shares originated from option exercises and RSU grants dating back to May 2020.

Who Is Vivek Ramaswamy?

https://www.readtheprofile.com/p/who-is-vivek-ramaswamy
This article provides a detailed profile of Vivek Ramaswamy, the Republican nominee for governor of Ohio. It covers his background as a biotech entrepreneur, his net worth, his political career including a presidential run and a brief stint co-leading the Department of Government Efficiency, and his current gubernatorial campaign. The profile also touches on his personal life, education, notable deals, and controversies.

Technical Reactions to ROIV Trends in Macro Strategies

https://news.stocktradersdaily.com/news_release/39/Technical_Reactions_to_ROIV_Trends_in_Macro_Strategies_110326091002_1793715002.html
This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) using AI models to suggest trading strategies. It highlights strong sentiment supporting an overweight bias, outlines three distinct strategies (Position Trading, Momentum Breakout, Risk Hedging), and provides multi-timeframe signal analysis with support and resistance levels. The report emphasizes an exceptional risk-reward setup targeting a 9.0% gain.
Advertisement

Under a trading plan, Roivant Sciences (ROIV) president sells 200,000 shares at a $36.59 average.

https://www.stocktitan.net/sec-filings/ROIV/form-4-roivant-sciences-ltd-insider-trading-activity-cd27de9812cc.html
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker sold 200,000 common shares of ROIV on October 28, 2026, at a weighted average price of $36.59 per share. The sale, made under a Rule 10b5-1 trading plan adopted on June 30, 2026, occurred in multiple transactions ranging from $36.18 to $36.95. After the transaction, Eric Venker directly held 1,199,154 common shares.

How Investors May Respond To Roivant Sciences (ROIV) Phase 3 Uveitis Win

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/how-investors-may-respond-to-roivant-sciences-roiv-phase-3-u-1
Roivant Sciences (ROIV) and Priovant Therapeutics announced positive Phase 3 results for brepocitinib in non-infectious uveitis, meeting primary and key secondary endpoints with a favorable safety profile. The drug demonstrated a steroid-sparing role, which could significantly influence its positioning for approval and reshape Roivant Sciences' investment narrative. The company is currently loss-making, but analysts project substantial revenue and earnings growth by 2029, with significant potential upside in its stock price.

Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 28 October

https://ca.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-eric-venker-president--immunovant-ceo-for-28-october-93CH-4919390
This article reports on a Form 4 filing for Roivant Sciences Ltd. concerning Eric Venker, who serves as President and CEO of Immunovant. The filing is for transactions that occurred on October 28th.

Get the Facts: Ad attacks Ramaswamy over pharmaceutical drug venture — context behind claims

https://www.wlwt.com/article/get-the-facts-ad-attacks-ramaswamy-pharmaceutical-drug/74287619
An ad from "Ohioans for Amy Acton and David Pepper" criticizes Vivek Ramaswamy's involvement with the drug intepirdine, which was explored as an Alzheimer's treatment. Ramaswamy founded Roivant Sciences and Axovant Sciences, purchasing intepirdine from GlaxoSmithKline. Although initially promoted with preliminary results, the drug ultimately failed Phase 3 trials in 2018.

Roivant Sciences Ltd. Tokenized Stock (Ondo) price today, ROIVon to USD live price, marketcap and chart

https://coinmarketcap.com/currencies/roivant-sciences-ltd-tokenized-stock-ondo/
This CoinMarketCap page provides information on Roivant Sciences Ltd. Tokenized Stock (Ondo), including its current price, market capitalization, and chart. It notes that this is a preview page and directs users to listing review criteria for more details on listing tiers. The page also lists other popular real-world assets and most visited cryptocurrencies.
Advertisement

A six-figure gift goes to No Patient Left Behind as Roivant Social Ventures closes its institutional work.

https://www.stocktitan.net/news/ROIV/roivant-social-ventures-announced-support-of-no-patient-left-behind-js1x5lxxxrdr.html
Roivant Social Ventures (RSV) announced a six-figure legacy donation to No Patient Left Behind (NPLB) as RSV concludes its own institutional operations. This gift aims to advance drug affordability and access while preserving incentives for medical innovation. NPLB will continue RSV's mission to improve healthcare access and affordability, educating stakeholders and policymakers on balanced solutions.

Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $56

https://www.moomoo.com/news/post/1002819901/citi-maintains-roivant-sciences-roivus-with-buy-rating-maintains-target
Citi has reiterated its Buy rating on Roivant Sciences (ROIV.US), maintaining a target price of $56. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.

Citigroup raises Roivant Sciences price target to $56, maintains Buy

https://scanx.trade/stock-market-news/companies/citigroup-raises-roivant-sciences-price-target-56-maintains-buy/54774881
Citigroup has increased its price target for Roivant Sciences from $46 to $56, while reiterating a Buy rating on the stock. This adjustment, made by analyst Samantha Semenkow, reflects a stronger valuation perspective and continued confidence in the company's strategic direction and potential for value realization among institutional investors. The $10 increase suggests an upward revision in fundamental assumptions or discounted cash flow models, indicating a reassessment of the company's long-term earnings potential or pipeline success probability.

Form 144 Roivant Sciences Ltd. For: 28 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-roivant-sciences-ltd-for-28-october-93CH-4911648
The article reports on the filing of Form 144 by Roivant Sciences Ltd. for October 28. This filing is a regulatory notice indicating an intent to sell restricted stock. The content includes a brief mention of the company's stock performance and is primarily a straightforward announcement.

Form 144 Roivant Sciences Ltd. For: 28 October By Investing.com

https://in.investing.com/news/stock-market-news/form-144-roivant-sciences-ltd-for-28-october-93CH-5662311
Investing.com reported on a Form 144 filing by Roivant Sciences Ltd. for October 28th. Form 144 filings typically indicate an insider's intent to sell restricted or controlled securities. The article does not provide specific details from the filing but confirms its submission.
Advertisement

Melissa Epperly Receives 513 Roivant Shares, Retains 15,351 After Tax Withholding Net Settlement

https://kalkinemedia.com/us/news/announcements/melissa-epperly-receives-513-roivant-shares-retains-15351-after-tax-withholding-net-settlement
Melissa Epperly, a Director at Roivant Sciences Ltd., received 513 common shares as an award on October 23, 2026, which vested immediately under the company's compensation plan. On the same day, 116 shares were sold at $36.49 each to cover tax withholding obligations. Following these transactions, Epperly's direct beneficial ownership in Roivant Sciences Ltd. totaled 15,351 common shares.

Form 4 Roivant Sciences Ltd.: Ilan Oren (Director) For: 23 October

https://uk.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-ilan-oren-director-for-23-october-93CH-4935805
This article reports on a Form 4 filing for Roivant Sciences Ltd., indicating an insider transaction by Ilan Oren, a Director, related to October 23. Form 4 filings disclose changes in beneficial ownership of securities by a company's officers, directors, and major shareholders. The specific details of the transaction are not provided in the article snippet.

Form 4 Roivant Sciences Ltd.: James C. Momtazee (Director) For: 23 October

https://uk.investing.com/news/stock-market-news/form-4-roivant-sciences-ltd-james-c-momtazee-director-for-23-october-93CH-4935802
This article reports on a Form 4 filing for Roivant Sciences Ltd., indicating that James C. Momtazee, a Director, made a transaction on October 23. The filing is an official disclosure of changes in company ownership by insiders. The article also provides the stock symbol ROIV and its current price performance.

A director receives 383 Roivant Sciences (ROIV) shares, with 77 withheld for taxes.

https://www.stocktitan.net/sec-filings/ROIV/form-4-roivant-sciences-ltd-insider-trading-activity-681b3872ab80.html
Roivant Sciences Ltd. director James C. Momtazee was awarded 383 Common Shares on October 23, 2026, under the Non-Employee Director Compensation Plan. On the same date, 77 of these shares were net-settled at $36.49 per share to cover tax withholding obligations. After this transaction, Momtazee directly holds 112,265 Common Shares.

Form 4 Roivant Sciences Ltd. For: Oct 23 Filed by: MOMTAZEE JAMES C

https://www.streetinsider.com/SEC+Filings/Form+4+Roivant+Sciences+Ltd.+For%3A+Oct+23+Filed+by%3A+MOMTAZEE+JAMES+C/27242886.html
James C. Momtazee, a director at Roivant Sciences Ltd. (ROIV), filed a Form 4 disclosing recent transactions involving common shares. On October 23, 2026, Momtazee acquired 383 common shares as an award from the company's Non-Employee Director Compensation Plan and simultaneously disposed of 77 shares through a net settlement to cover tax withholding obligations at a price of $36.49 per share. Following these transactions, Momtazee beneficially owns 112,265 common shares.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement